Nebenwirkungen · Carmustine medac (previously Carmustine Obvius)
Carmustine medac 100 mg powder and solvent for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-226519 · Präparat HOS-217596
Common Anorexia, constipation, diarrhoea, stomatitis. Hepatobiliary disorders Common Hepatotoxicity, reversible, delayed up to 60 days after administration (high-dose therapy and dose-limiting), manifested by: - bilirubin, reversible increase - alkaline phosphatase, reversible increase - SGOT, reversible increase. Skin and subcutaneous tissue disorders Very Dermatitis with topical use improves with common reduced concentration of compounded product, hyperpigmentation, transient, with accidental skin contact.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-03T11:11:01Z · SHA-256 9664762dde397fcc1888249f30543eb5a860303e3ec119e07ff27175b5976fe5 · Passage 64a3ab34a557ebd6bfbcc050d0d8842ce126d617353027d57d8cb0ae6af7acdd · Zeichen 3456–4457 im Abschnitt